|4-(叔丁基)-N-(6-(2-羟基乙氧基)-5-(2-甲氧基苯氧基)-[2,2’-联吡啶]-4-基)苯磺酰胺水合物|CsnPharm

CAS No.: 157212-55-0

波生坦水合物 Catalog No. CSN10481

Synonyms: Ro 47-0203;Ro-47-0203 Hydrate;Benzenesulfonamide Hydrate

Bosentan is an endothelin (ET) receptor antagonist of ET-A (Ki = 4.7 nM) and ET-B (Ki = 95 nM).

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

靶点 Endothelin-1/Endothelin Receptor A

Ki:4.7nM Endothelin-2/Endothelin recetpor B

Ki:95nM
描述G protein-coupled receptor (GPCR) agonists through their receptors can transactivate protein tyrosine kinase receptors such as epidermal growth factor receptor and serine/threonine kinase receptors most notably transforming growth factor (TGF)‐β receptor (TβRI). Several GPCR agonists such as Ang II, thrombin, ET-1 can mediate the transactivation of a multitude of protein tyrosine kinase receptors^[3]. Endothelin (ET) is an endothelium-derived 21-residue vasoconstrictor peptide. The ETs have three distinct isoforms, namely ET-1, ET-2, and ET-3. ET-1 is the most abundant isoform and the best characterized in vivo, and it is the only one that is constitutively released by the vascular endothelium^[4]. Bosentan hydrate (BST) is a competitive dual endothelin receptor antagonist that is nonselective for both endothelin A and endothelin B receptors with a Ki of 4.1 - 4.7 nM^[5]. It decreases both pulmonary vascular resistance and systemic vascular resistance and hence increases cardiac output without increasing the heart rate^[6]. In a vivo study, the rats were intragastrically administered with 100 mg/kg bosentan half an hour after Paraquat exposure, and then once a day. After bosentan administration, the ET-1 and TGF-β1 content of the serum and lungs gradually decreased and were markedly lower than in the Paraquat group on the 21st day which indicated that early treatment with bosentan after Paraquat poisoning may be helpful in ameliorating lung injury and decreasing lung fibrosis^[4]. In a study, bosentan was given orally (1000 mg b.i.d.) for 14 days to patients who were also being treated for chronic heart failure (CHF) with digitalis, angiotensin-converting enzyme inhibitors (ACEIs) and diuretics and the results demonstrated that addition of bosentan to ongoing therapy for patients with CHF reduced systemic and pulmonary vascular resistance and increased cardiac index, without affecting heart rate. Bosentan treatment of patients with CHF already receiving ACEIs and diuretics significantly decreased plasma aldosterone levels^[5].
参考文献

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 1.7555 mL
- 8.7776 mL
- 17.5553 mL
- 5 mM
- 0.3511 mL
- 1.7555 mL
- 3.5111 mL
- 10 mM
- 0.1756 mL
- 0.8778 mL
- 1.7555 mL

技术信息

CAS号

157212-55-0

储存条件

粉末: Sealed in dry,Room Temperature

液体: -20°C:3-6 月 -80°C:12月

分子式

C27H31N5O7S

运输

蓝冰

分子量

569.63

别名

Ro 47-0203;Ro-47-0203 Hydrate;Benzenesulfonamide Hydrate;波生坦水合物

溶解度

DMSO	98.0 mg/mL (172.0 mM)
Water	Insoluble
Ethanol	2.0 mg/mL (3.5 mM)

动物实验配方

2% DMSO+30% PEG 300+2% Tween 80+water

5 mg/mL

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

靶点	Description	IC50
Endothelin-1/Endothelin Receptor A		Ki:4.7nM
Endothelin-2/Endothelin recetpor B		Ki:95nM

波生坦水合物 Catalog No. CSN10481

靶点选择性

请登录您的专属账户

确认信息